Endometrial cancer presentation is associated with social determinants of health in a public healthcare system: A population-based cohort study.

Abstract:

OBJECTIVE:Delay in diagnosis of endometrial cancer may be associated with disease progression and impact management and outcomes. Social and cultural barriers influence recognition of symptoms and self-advocacy in seeking care. Associations between social determinants of health (SDH) and disease presentation have been shown in some settings. Our objective was to investigate these in Ontario's universal access system. METHODS:Endometrial cancer patients in Ontario diagnosed 2009-2017 were identified, and clinical, social and demographic information extracted from administrative databases using ICES (Institute of Evaluative Sciences) algorithms. SDH were quantified using previously validated marginalization indices for material deprivation, residential instability and ethnic concentration. Associations between SDH and disease stage were explored using logistic regression. RESULTS:20,228 patients were identified. 73% of cancers were confined to the uterus. Stage distribution differed across marginalization quintiles (p < 0.001) with advanced disease found more frequently in highly marginalized patients: 29% vs. 25% (p < 0.001) for material deprivation, OR = 1.06/quintile (CI, 1.03-1.09); 29% vs. 24% (p < 0.001) for ethnic concentration, OR = 1.05/quintile (CI, 1.03-1.08); 30% vs. 27% (p < 0.001) for residential instability, OR = 1.02/quintile (CI, 1.0-1.05). Marginalization was persistently associated with advanced disease on multivariable analysis adjusted for age, comorbidity score, obesity and disease histology (OR = 1.05/quintile, CI 1.01-1.10, p = 0.03). CONCLUSIONS:Socioeconomic marginalization is associated with advanced disease at presentation among endometrial cancer patients in Ontario. Mediators of this association are likely multifactorial, and need to be further investigated in order to create opportunities for improved patient education and advocacy, redistribution of resources and the promotion of health equity.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Helpman L,Pond GR,Elit L,Anderson LN,Seow H

doi

10.1016/j.ygyno.2020.04.693

subject

Has Abstract

pub_date

2020-07-01 00:00:00

pages

130-136

issue

1

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(20)30993-8

journal_volume

158

pub_type

杂志文章
  • Large B-cell lymphoma of the uterine corpus: case report with immunohistochemical and molecular study.

    abstract::Primary lymphoma of the uterine corpus (PLUC) is an extremely rare neoplasm. We report a case of PLUC in a 78-year-old woman with vaginal bleeding without hepatosplenomegaly, adenopathies, or bone marrow infiltration, classified as stage I. A diagnosis of diffuse large B-cell lymphoma was made in endometrial curettage...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1997.4679

    authors: Alvarez A,Ortiz JA,Sacristán F

    更新日期:1997-06-01 00:00:00

  • Incidence and risk factors for lower limb lymphedema associated with endometrial cancer: Results from a prospective, longitudinal cohort study.

    abstract:BACKGROUND:Evidence on the incidence and risk factors for lower limb lymphedema (LLL) associated with endometrial cancer is limited. Our objective was to use data from a prospective, longitudinal gynecological cancer cohort study to determine LLL incidence up to 24 months post-diagnosis of endometrial cancer and to exp...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.04.702

    authors: Pigott A,Obermair A,Janda M,Vagenas D,Ward LC,Reul-Hirche H,Hayes SC

    更新日期:2020-08-01 00:00:00

  • High-risk metastatic gestational trophoblastic disease: further stratification into two clinical entities.

    abstract::Forty-two of sixty-seven patients (62.7%) treated for high-risk metastatic trophoblastic disease achieved and maintained complete remissions. The survival rate was significantly improved in those patients with scores lower than 8 according to a modification of the World Health Organization (WHO) prognostic scoring sys...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(89)90106-6

    authors: Gordon AN,Gershenson DM,Copeland LJ,Stringer CA,Morris M,Wharton JT

    更新日期:1989-07-01 00:00:00

  • Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study.

    abstract:OBJECTIVE:A phase II study was conducted to determine the efficacy of oxaliplatin therapy in patients with previously treated squamous cell carcinoma of the cervix. METHODS:Eligible patients were to have measurable disease and not more than one prior chemotherapy regimen that could include carboplatin or cisplatin but...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1016/s0090-8258(03)00253-1

    authors: Fracasso PM,Blessing JA,Wolf J,Rocereto TF,Berek JS,Waggoner S

    更新日期:2003-07-01 00:00:00

  • Characterization of peripheral blood and ovarian cancer-infiltrating lymphocytes: effect of HIV infection on phenotypic expression and proliferative response.

    abstract::A study that focused on the identification of the phenotype and proliferative responses of peripheral blood and ovarian cancer-infiltrating lymphocytes in a patient with stage III ovarian cancer who had human immunodeficiency virus infection is presented. Monoclonal antibodies and flow cytometry were used to determine...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1994.1126

    authors: Guidozzi F,Reddy S,Wadee A

    更新日期:1994-05-01 00:00:00

  • Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer.

    abstract:OBJECTIVE:While primary cisplatin-based intraperitoneal chemotherapy has been shown to favorably impact survival in small-volume residual advanced ovarian cancer, there is a need to develop strategies that improve the effectiveness of this approach. METHODS:A multi-center phase 2 trial was conducted that added intrave...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2009.04.023

    authors: Smith HO,Moon J,Wilczynski SP,Tiersten AD,Hannigan EV,Robinson WR,Rivkin SE,Anderson GL,Liu PY,Markman M

    更新日期:2009-08-01 00:00:00

  • The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.

    abstract:OBJECTIVE:To determine if the timing of normalization of CA-125 levels during primary chemotherapy for epithelial ovarian cancer (EOC) could predict survival. METHODS:Patients who reached a complete clinical response for EOC with primary taxane/platinum-based chemotherapy were eligible. Patient demographics, chemother...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2009.04.019

    authors: Rocconi RP,Matthews KS,Kemper MK,Hoskins KE,Huh WK,Straughn JM Jr

    更新日期:2009-08-01 00:00:00

  • Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007.

    abstract::Advances in surgery and chemotherapy have improved the 5-year survival for patients with epithelial ovarian cancer, but have not impacted on the ultimate rate of cure in a disease that is diagnosed in late stage and that recurs in the majority of patients. "Omic" technologies promise to define genetically driven aberr...

    journal_title:Gynecologic oncology

    pub_type: 共识发展会议,杂志文章

    doi:10.1016/j.ygyno.2007.11.014

    authors: Ashworth A,Balkwill F,Bast RC,Berek JS,Kaye A,Boyd JA,Mills G,Weinstein JN,Woolley K,Workman P

    更新日期:2008-03-01 00:00:00

  • Gemcitabine in cervical cancer.

    abstract:OBJECTIVE:Recurrent and advanced cervical cancers are associated with high mortality and a lack of effective treatment options, especially for women who are poor candidates for surgery or radiation therapy. The broad clinical effectiveness and low toxicity of gemcitabine in other human malignancies suggest that it migh...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0090-8258(03)00338-x

    authors: Mutch DG,Bloss JD

    更新日期:2003-08-01 00:00:00

  • Assessment of sexual difficulties associated with multi-modal treatment for cervical or endometrial cancer: A systematic review of measurement instruments.

    abstract:BACKGROUND:Practitioners and researchers require an outcome measure that accurately identifies the range of common treatment-induced changes in sexual function and well-being experienced by women after cervical or endometrial cancer. This systematic review critically appraised the measurement properties and clinical ut...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2016.08.332

    authors: White ID,Sangha A,Lucas G,Wiseman T

    更新日期:2016-12-01 00:00:00

  • Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer.

    abstract:OBJECTIVES:We previously reported a 10% rate of catheter complications, including inflow obstruction and infection, using a fenestrated catheter to administer intraperitoneal (i.p.) chemotherapy for ovarian cancer. Because of recent reports of higher rates of catheter complications, we performed this study to update ou...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2007.12.004

    authors: Black D,Levine DA,Nicoll L,Chou JF,Iasonos A,Brown CL,Sonoda Y,Chi DS,Leitao MM,Abu-Rustum NR,Ferguson SE,Barakat RR

    更新日期:2008-04-01 00:00:00

  • Vulvovaginal melanoma: report of seven cases and literature review.

    abstract::Five cases of primary vaginal melanoma were treated at UCLA Medical Center between 1976 and 1986. Two additional cases of melanoma arising at the junction of the vulva and vagina are presented. One of seven (13%) patients is alive, with a median time to recurrence of 7 months, and median survival of 31 months. Four of...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/0090-8258(89)90603-3

    authors: Brand E,Fu YS,Lagasse LD,Berek JS

    更新日期:1989-04-01 00:00:00

  • Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIA cervical cancer.

    abstract:OBJECTIVE:To determine the effectiveness of chemotherapy alone as postoperative adjuvant therapy for intermediate- and high-risk cervical cancer. METHODS:The study group comprised of 65 consecutive patients with stage IB or IIA squamous cell or adenosquamous cervical cancer who were initially treated with radical hyst...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2006.04.019

    authors: Takeshima N,Umayahara K,Fujiwara K,Hirai Y,Takizawa K,Hasumi K

    更新日期:2006-11-01 00:00:00

  • Class II radical hysterectomy shows less morbidity and good treatment efficacy compared to class III.

    abstract::Treatment of 102 patients with cancer of the cervix by class II and III radical hysterectomy was reviewed to compare the operative morbidity and efficacy of class II radical hysterectomy for select cases. Of the 102 patients, 21 had a class II hysterectomy, whereas 81 patients had a class III hysterectomy. The class I...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(91)90078-j

    authors: Photopulos GJ,Zwaag RV

    更新日期:1991-01-01 00:00:00

  • Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors.

    abstract:OBJECTIVE:Heredity is a major cause of ovarian cancer and during recent years the contribution from germline mismatch repair (MMR) gene mutations linked to Lynch syndrome has gradually been recognized. METHODS:We characterized clinical features, tumor morphology and mismatch repair defects in all ovarian cancers ident...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2011.02.010

    authors: Ketabi Z,Bartuma K,Bernstein I,Malander S,Grönberg H,Björck E,Holck S,Nilbert M

    更新日期:2011-06-01 00:00:00

  • The role of cancer antigen 125 (CA 125) in the management of ovarian epithelial carcinomas.

    abstract::From June 1, 1984, to May 31, 1985, 98 cases of epithelial ovarian carcinomas were assessed and followed prospectively using a new murine monoclonal antibody OC 125 which detects the antigen CA 125. Serous tumors comprised 43.7% of cases, mucinous tumors 20.4%, endometrioid tumors 16%, and other epithelial tumors 19.4...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(88)90042-x

    authors: Altaras MM,Goldberg GL,Levin W,Bloch B,Darge L,Smith JA

    更新日期:1988-05-01 00:00:00

  • The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists.

    abstract:OBJECTIVE:Recent randomized controlled data suggest that neoadjuvant chemotherapy (NACT) with interval debulking (ID) may produce similar overall survival and progression free survival compared to standard primary cytoreduction followed by chemotherapy. The object of our study was to assess current patterns of care amo...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2010.06.021

    authors: Dewdney SB,Rimel BJ,Reinhart AJ,Kizer NT,Brooks RA,Massad LS,Zighelboim I

    更新日期:2010-10-01 00:00:00

  • Methotrexate-resistant mechanisms in human choriocarcinoma cells.

    abstract::Choriocarcinoma cells grown in the presence of methotrexate (MTX) developed resistance in two ways. HCCM-derived sublines (relatively high MTX resistance) produced enhanced levels of dihydrofolate reductase (DHFR) and had impaired transport of MTX. Altered transport was the primary determinant of response in CC1-deriv...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(89)90095-4

    authors: Sakai K,Wake N,Fujino T,Yasuda T,Kato H,Fujimoto S,Fujinaga K

    更新日期:1989-07-01 00:00:00

  • Management of early ovarian cancer: germ cell and sex cord-stromal tumors.

    abstract::Malignant ovarian germ cell tumors (OGCT) and sex cord-stromal tumors (OSCST), each of which account for less than 5% of all ovarian malignancies, are much less common than epithelial ovarian cancer. In young patients suspected of having an OGCT, laparotomy is initially indicated for both diagnosis and treatment. For ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Gershenson DM

    更新日期:1994-12-01 00:00:00

  • Disparities in surgical management of endometrial cancers in a public healthcare system: A question of equity.

    abstract:OBJECTIVE:Timely surgery has been shown to impact outcome in endometrial cancer patients. Social determinants of health (SDH) are associated with adverse cancer outcomes. We sought to evaluate the association of SDH with surgical treatment indicators in endometrial cancer patients in a public healthcare system. METHOD...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.08.029

    authors: Helpman L,Pond GR,Elit L,Anderson LN,Seow H

    更新日期:2020-11-01 00:00:00

  • Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.

    abstract:OBJECTIVE:The first-line chemotherapy for ovarian cancer is based on a combination of platinum and taxane. To date, no reliable predictive biomarker has been recognized that is capable of identifying patients with pre-existing resistance to these agents. Here, we have established an integrated database and identified t...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.01.006

    authors: Fekete JT,Ősz Á,Pete I,Nagy GR,Vereczkey I,Győrffy B

    更新日期:2020-03-01 00:00:00

  • The malignant potential of small cystic ovarian tumors in women over 50 years of age.

    abstract:OBJECTIVE:The aim of this study was to determine the risk of malignancy in cystic ovarian tumors < 10 cm in diameter in asymptomatic postmenopausal women or women >or =50 years of age. METHODS:All cystic ovarian tumors detected by transvaginal sonography screening in asymptomatic postmenopausal women or women > or =50...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1998.4965

    authors: Bailey CL,Ueland FR,Land GL,DePriest PD,Gallion HH,Kryscio RJ,van Nagell JR Jr

    更新日期:1998-04-01 00:00:00

  • Long-term results of fertility-sparing treatment for early-stage cervical cancer.

    abstract:OBJECTIVE:To evaluate the long-term outcomes of young early stage cervical cancer patients wishing to preserve their childbearing potential. METHODS:Data of young (aged <40 years) patients with early stage cervical cancer were prospectively collected. All patients with stage IA2, IB1 and IB2 cervical cancer were inclu...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2019.04.007

    authors: Bogani G,Chiappa V,Vinti D,Somigliana E,Filippi F,Murru G,Murgia F,Martinelli F,Ditto A,Raspagliesi F

    更新日期:2019-07-01 00:00:00

  • Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.

    abstract:OBJECTIVES:This trial was conducted to evaluate the safety and efficacy of cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix. SUBJECTS AND METHODS:All women had measurable histologically confirmed squamous cell cervical cancer and a GOG performance status less than or equal to 2. T...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2005.09.009

    authors: Brewer CA,Blessing JA,Nagourney RA,McMeekin DS,Lele S,Zweizig SL

    更新日期:2006-02-01 00:00:00

  • Beyond prophylaxis: Extended risk of venous thromboembolism following primary debulking surgery for ovarian cancer.

    abstract:OBJECTIVE:To determine the incidence and risk factors for venous thromboembolism (VTE) within six months after primary debulking surgery (PDS) for epithelial ovarian cancer (EOC). METHODS:In a historical cohort, we estimated the cumulative incidence of clinically diagnosed VTE within 6 months among consecutive women w...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2018.11.021

    authors: Wagner BE,Langstraat CL,McGree ME,Weaver AL,Sarangi S,Mokri B,Dowdy SC,Cliby WA,Kumar A,Bakkum-Gamez JN

    更新日期:2019-02-01 00:00:00

  • Tumorigenesis of K-ras mutation in human endometrial carcinoma via upregulation of estrogen receptor.

    abstract:OBJECTIVE:To investigate the tumorigenesis of mutant [12Asp]-K-ras in endometrial carcinoma and its relationship with ER. METHODS:We constructed pcDI-[12Asp]K-ras4B by inserting full-length [12Asp]K-ras4B from human endometrial carcinoma Hec-1A cells, into pcDI vector. Cell proliferation of NIH3T3 after transfection w...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.10.016

    authors: Tu Z,Gui L,Wang J,Li X,Sun P,Wei L

    更新日期:2006-05-01 00:00:00

  • Successful salvage of a relapsed high risk gestational trophoblastic neoplasia patient using capecitabine.

    abstract:BACKGROUND:Although most patients at high risk of Gestational Trophoblastic Neoplasia (GTN) respond to standard treatments, there is a group of patients that will die because of it. The use of new single or combination drugs in this population has become a priority. CASE REPORT:We present the case of a relapsed high r...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2007.04.002

    authors: Bianconi M,Jankilevich G,Otero S,Nassif J,Storino C

    更新日期:2007-07-01 00:00:00

  • The impact of written information and counseling (WOMAN-PRO II Program) on symptom outcomes in women with vulvar neoplasia: A multicenter randomized controlled phase II study.

    abstract:OBJECTIVE:To determine whether written information and/or counseling based on the WOMAN-PRO II Program decreases symptom prevalence in women with vulvar neoplasia by a clinically relevant degree, and to explore the differences between the 2 interventions in symptom prevalence, symptom distress prevalence, and symptom e...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.ygyno.2017.04.024

    authors: Raphaelis S,Mayer H,Ott S,Mueller MD,Steiner E,Joura E,Senn B

    更新日期:2017-07-01 00:00:00

  • Necessity of routine cardiac evaluation in patients receiving pegylated liposomal doxorubicin for gynecologic cancer.

    abstract:OBJECTIVE:Pegylated liposomal doxorubicin (PLD) has similar reported clinical efficacy compared with conventional doxorubicin with less cardiotoxicity. The manufacturer of PLD advises that cardiac function should be evaluated with endomyocardial biopsy, echocardiography or multigated radionucleotide scan (MUGA) pre-tre...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2019.09.009

    authors: Dioun SM,Vilardo N,Goldberg GL,Gressel GM

    更新日期:2019-11-01 00:00:00

  • Paratubal borderline serous tumors.

    abstract:BACKGROUND:While ovarian borderline tumors are common, their fallopian tube counterparts are extremely rare. We describe the first case of a serous borderline paratubal tumor with a review of the literature on paratubal and tubal low malignant potential tumors. CASE:A 26 year-old woman presented with acute onset of sh...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.12.019

    authors: Seamon LG,Holt CN,Suarez A,Richardson DL,Carlson MJ,O'Malley DM

    更新日期:2009-04-01 00:00:00